Elucidata and Sapien Biosciences Announce Strategic Partnership to Transform Biobank Assets into high quality AI Products
Through this collaboration, Sapien will harness Elucidata's platform to integrate, standardize, and enrich its vast repository of biospecimens and curated clinical data, making them accessible for predictive modeling, synthetic data generation, and advanced genomics research. The partnership reflects a shared focus on turning real-world patient data into high-value actionable insights that drive precision medicine and improve outcomes worldwide.
With access to over 300,000 patient samples across oncology, cardiology, autoimmune, inflammation, neurology, and other diseases, Sapien operates at a scale matched by few biobanks worldwide. This includes more than 85,000 cancer patients, increasingly paired with digitized histopathology images, genomic profiles, and structured longitudinal clinical data, making it one of the top 10 biobanks globally and the largest integrated resource for Asian patient data.
'At Sapien, we believe that deeply characterized patient data especially from underrepresented populations like those in India can catalyze more inclusive and effective diagnostics and therapies worldwide,' said Dr. Jugnu Jain, CEO and Co-founder of Sapien Biosciences. 'This partnership with Elucidata enables us to convert our rich biological and clinical datasets into interoperable, AI-ready formats, unlocking their potential for translational research, patient stratification, and precision drug development.'
The first phase of the collaboration will focus on building AI models that infer genomic and transcriptomic insights from digital pathology images. By using NGS-annotated slides from Sapien's cancer biobank, the project will enable the generation of synthetic multi-modal datasets essential for next-generation diagnostic tools and tissue-sparing research strategies. This is particularly valuable for rare cancers and limited biopsy specimens.
'Sapien's scale, sample quality, and data depth make it a critical partner in our mission to democratize access to high quality, AI-ready biomedical data,' said Dr. Abhishek Jha, CEO and Co-founder of Elucidata. 'By applying our Polly platform to Sapien's datasets, we can bridge the gap between fragmented sample collections and next-gen AI models that accelerate target discovery and biomarker validation.'
In addition to oncology, the partnership will explore multi-disease use cases across Sapien's biobank, including cardiovascular, autoimmune, and neurological disorders, building synthetic clinicogenomic datasets that support pharma R&D and companion diagnostic development.
'This partnership between Elucidata and Sapien Biosciences brings together Sapien's extensive, high-quality biobank resources and Elucidata's expertise in AI-powered data integration. By making rich biospecimens and clinical datasets AI-ready, this collaboration has the potential to accelerate global innovation and help reduce the complexity of human biology for research and patient care,' said Dr. Navjot Singh, advisor of Elucidata.io and healthcare leader with 22 years of expertise in strategy, technology, and innovation, most recently as a Senior Partner at McKinsey & Company.
Elucidata recently ranked 7th in the Broad Institute's Autoimmune Disease Machine Learning Challenge and recently won the National Cancer Institute's Cancer Research Data Commons AI Data Readiness Challenge, highlighting its leadership in data-centric AI for life sciences.
About Elucidata
Elucidata is a data-first AI company that accelerates life sciences R&D by converting fragmented biomedical datasets into harmonized, AI-ready assets. Its proprietary Polly platform integrates EHRs, genomics, imaging, and clinical trial data for seamless downstream analysis and model development. Headquartered in San Francisco with offices across the U.S. and India, Elucidata supports over 70 pharma and diagnostics clients, and has contributed to 16 drug programs progressing toward FDA approvals. Recognized by the National Cancer Institute and Fast Company for its innovation in biotech, Elucidata is enabling a new era of data-driven discovery. Visit elucidata.io for more information.
About Sapien Biosciences
Founded in partnership with Apollo Hospitals, Sapien Biosciences is India's premier multi-disease biobank and a leader in Indian real-world evidence (RWE) for personalized medicine. With access to more than 300,000 patients' samples including 2 million pathology samples, Sapien offers FFPE tissues, blood, and liquid biopsy samples along with annotated histopathology slides and longitudinal clinical data. Its resources support a broad range of applications from AI/ML modeling and multi-omics research to drug screening in patient tumor-derived cells and biomarker discovery. Sapien has published over 10 peer-reviewed studies using Indian patient data and collaborates with leading diagnostic and pharma companies to reduce the representation gap in global omics datasets. Learn more at www.sapienbio.co.in.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
WD-40 shifts supply chain to dodge tariffs
This story was originally published on Supply Chain Dive. To receive daily news and insights, subscribe to our free daily Supply Chain Dive newsletter. Dive Brief: WD-40 Company's initiative to decentralize its supply chain and bring sourcing closer to customers is offsetting the impact of tariffs, according to its July earnings call. Since the start of the fiscal year on Sept. 1, the chemical company has strengthened global partnerships with key suppliers, which improved efficiencies, optimized networks and brought cost savings that bolstered gross margins, executives said. "Where there is, particularly with our Americas region, some tariff exposure, particularly around steel cans with the tariffs, we are managing to offset that globally in terms of countermeasures from supply chain initiatives, making it virtually a wash globally for us," CFO Sara Hyzer told analysts. Dive Insight: WD-40 is one of several brand manufacturers modifying their supply chains to mitigate the impact of tariffs. Others include Clorox tapping alternative sourcing, Colgate-Palmolive shifting production and Procter & Gamble initiating a supply chain reorganization. WD-40's diversified supply chain will minimize the effect of potential tariffs by sourcing raw materials and manufacturing products close to the company's customers and end users, CEO Steve Brass said during an April earnings call. "This decentralized nature of our supply chain helps a lot," he said. "We've got a lot of supply chain optimization measures happening this fiscal year." In China, the company has avoided retaliatory tariffs by manufacturing locally for Asian markets, using China nationals to operate its business there, Brass said. "Within China at the moment, we are kind of seen as a local brand in many places we operate around the world." In Dubai, the company partnered with a manufacturer to deliver products to customers in the region within five or seven days, much quicker than the one month previously required for maritime shipments, he said in the July call. The change has also meant local partners could reduce their on-hand inventory. Nevertheless, Brass acknowledged that tariffs could impact the company's markets in the Americas, especially Mexico and Canada. The Americas account for 6% of WD-40's global business, he said in the company's April earnings call. As a precaution, the company increased inventory in specific markets to reduce the immediate impact of tariffs, he added. WD-40's supply chain shifts should help the household products company reach its gross margin goal of 55% to 56% during the current fiscal year, one year earlier than initially planned, Hyzer said. "It is great to see our supply chain initiatives having an impact on our overall gross margin results," she said in the July call. After fiscal 2025 ends on Aug. 31, the company expects higher inflation and will likely need to "modestly adjust prices," Brass added. Recommended Reading WD-40 carries out first sustainability assessment among Tier 1 suppliers
Yahoo
7 minutes ago
- Yahoo
Empyrion integrates Nokia technology in new Seoul data centre
Empyrion Digital has implemented Nokia's data centre gateway and aggregation switches at its recently opened Gangnam Data Centre in Seoul, South Korea. Empyrion is engaged in the development and operation of data centres that facilitate the connection and expansion of digital ecosystems across major Asian cities, catering to both hyperscale and enterprise colocation companies. Empyrion Digital product and infrastructure chief strategy officer Yongsuk Choi said: 'We are excited to partner with Nokia to use their data centre solutions to provide a world-class network performance to our hyperscalers and enterprise customers in Korea. 'Nokia's strong track record, robust IP network solutions, combined with its strong regional supply chain and service footprint, made it a natural choice to strengthen our network.' With the surge in data traffic across the region, digital infrastructure providers are under significant pressure to maintain high-performance levels, stated Nokia. Nokia's advanced IP network solution features the 7250 Interconnect Router (IXR), which will serve as the data centre gateways and core network switches, alongside the 7210 Service Access System (SAS) that will function as the access switch for Empyrion's IT infrastructure. This collaboration is expected to enhance the reliability, scalability, and operational efficiency of Empyrion's data centre interconnect network. The Nokia 7250 IXR and 7210 SAS are tailored to meet the changing demands of digital infrastructure providers, enabling them to create networks that are ready for automation and more energy-efficient. Nokia Asia Pacific IP Networks head and vice president Kent Wong said: 'Nokia's state-of-the-art Data Centre Fabric solution will enable Empyrion Digital to better manage the growing data traffic demands while delivering high network performance. 'Our field-proven solutions are helping digital infrastructure providers across the Asia Pacific region to benefit from improved scalability and reliability while making the networks more energy efficient.' In January 2025, Nokia signed a multi-year patent licence agreement with Samsung, enabling the use of Nokia's video technologies in Samsung's television products. As part of the agreement, Samsung will make royalty payments to Nokia, although the specific terms were not disclosed. "Empyrion integrates Nokia technology in new Seoul data centre" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 hours ago
- Business Wire
Lura Health Announces Strategic Investment and Business Partnership with SCO Group to Advance Intraoral Health Monitoring
NEWARK, N.J.--(BUSINESS WIRE)-- Lura Health (UCHU Biosensors, Inc., Head Office: Newark, New Jersey, USA; CEO: Daniel Weinstein), a U.S. health tech company, today announced that it has entered into an investment and business partnership with SCO Group (Head Office: Chiyoda-ku, Tokyo, Japan; Chairman and CEO: Yusuke Tamai), a leading company in Japan's dental technology sector. The goal of the partnership is to deploy Lura Health's intraoral sensor technology into clinical use in Asia and expand its applications globally. Lura Health is developing wearable microsensors that can be worn inside the mouth, either attached to dental appliances or bonded directly to a tooth, to collect real-time biometric data such as pH levels and metabolites in saliva. The company is pioneering a new healthcare model that aims to "visualize whole-body health from within the oral cavity." Background and Purpose of the Partnership Lura Health has created the world's first continuous intraoral salivary monitoring sensor and is targeting medical device approval from the U.S. Food and Drug Administration (FDA) by early 2027. Following regulatory approval, Lura plans to expand its reach into Asian markets, starting with Japan. SCO Group is the operator of "Pay Light X," an integrated dental clinic management platform in Japan that supports appointment booking, diagnosis, payment, and aftercare. By integrating its sensor technology with SCO Group's clinical infrastructure, Lura Health aims to establish a new model for preventive health care in Japan. Key Points of the Partnership Continuous Monitoring with Intraoral Sensors Lura's sensors allow real-time monitoring of oral conditions such as pH and other salivary parameters. These measurements have the potential to supplement or replace conventional lab-based diagnostics in the future. Deployment through SCO Group's Platform By integrating with SCO Group's "Pay Light X," Lura aims to deliver its technology seamlessly to clinicians and patients. Joint pilot projects with Japanese universities and research institutions are expected to begin this fall to generate clinical validation and user feedback. Applications Beyond Dentistry Future use cases for the technology extend into sports performance monitoring, eldercare, and wellness, positioning Lura's sensors as a core tool in comprehensive personal health management. Statement from Daniel Weinstein, CEO of Lura Health "We at Lura Health are honored to announce our investment and business partnership with SCO Group, a leader in digital transformation within the Japanese dental industry. This collaboration represents a major step forward in our mission to enable preventive and user-friendly health monitoring through the diagnostic power of saliva. Our vision aligns deeply with SCO Group's commitment to improving the well-being of individuals through technology. Together, we will combine our sensor innovations with their extensive healthcare network to create tangible societal impact. We look forward to deploying our sensors in real-world clinical settings and co-developing patient-centered products based on live feedback from users in Japan." Partner Statement: Yusuke Tamai, Chairman and CEO of SCO Group "We are very pleased to partner with Lura Health, whose groundbreaking intraoral biosensing technology embodies the future of preventive healthcare. At SCO Group, we have long championed the integration of health technology into daily life, and this partnership allows us to take that mission to the next level. The oral cavity is a gateway to the body's health, yet remains one of the least-monitored areas. By utilizing saliva—a highly accessible source of biological data—we aim to convert invisible health risks into visible insights. Combined with our Pay Light X platform, we intend to build a comprehensive preventive care model that spans diagnosis, treatment, and everyday living." About Lura Health Lura Health is a U.S.-based medical device company developing intraoral microsensors that enable noninvasive, continuous monitoring of health biomarkers via saliva. Led by CEO Daniel Weinstein (Forbes 30 Under 30, Tufts University), the company specializes in microelectronics and biosignal processing and has drawn significant attention in fields such as oral health, diabetes, kidney disease, and therapeutic drug monitoring. LinkedIn:
